98%
921
2 minutes
20
Background: Cervical cancer shows a growing incidence and medical cost in recent years that has increased severe financial pressure on patients and medical insurance institutions. This study aimed to investigate the medical economic characteristics of cervical cancer patients with different payment modes within a Grade A tertiary hospital to provide evidence and suggestions for inpatient cost control and to verify the application of Gamma model in medical cost analysis.
Methods: The basic and cost information of cervical cancer cases within a Grade A tertiary hospital in the year 2011-2016 were collected. The Gamma model was adopted to analyze the differences in each cost item between medical insured patient and uninsured patients. Meanwhile, the marginal means of different cost items were calculated to estimate the influence of payment modes toward different medical cost items among cervical cancer patients in the study.
Results:: A total of 1321 inpatients with cervical cancer between the 2011 and 2016 were collected through the medical records system. Of the 1321 cases, 65.9% accounted for medical insured patients and 34.1% were uninsured patients. The total inpatient medical expenditure of insured patients was RMB 29,509.1 Yuan and uninsured patients was RMB 22,114.3 Yuan, respectively. Payment modes, therapeutic options as well as the recurrence and metastasis of tumor toward the inpatient medical expenditures between the two groups were statistically significant. To the specifics, drug costs accounted for 37.7% and 33.8% of the total, surgery costs accounted for 21.5% and 25.5%, treatment costs accounted for 18.7% and 16.4%, whereas the costs of imaging and laboratory examinations accounted for 16.4% and 15.2% for the insured patient and uninsured patients, respectively. As the effects of covariates were controlled, the total hospitalization costs, drug costs, treatment costs as well as imaging and laboratory examination costs showed statistical significance. The total hospitalization costs, drug costs, treatment costs as well as imaging and laboratory examination costs of insured patient were 1.33, 1.42, 1.52, and 1.44 times of uninsured patients.
Conclusions: The analysis of different payment modes toward the medical economic characteristics based on Gamma model is basically rational. Medical payment modes are having certain influence toward the hospitalization expenses of cervical cancer patients in an extent, as drug costs, treatment costs, and examination costs appear to be the main causes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830822 | PMC |
http://dx.doi.org/10.4103/0366-6999.225052 | DOI Listing |
JCO Glob Oncol
May 2025
Department of Obstetrics and Gynaecology, Stanford University School of Medicine, Stanford, CA.
Purpose: Expanding high-risk human papillomavirus (HPV) vaccine coverage in resource-constrained settings is critical to bridging the cervical cancer gap and achieving the global action plan for elimination. Mobile health (mHealth) technology via short message services (SMS) has the potential to improve HPV vaccination uptake. The mHealth-HPVac study evaluated the effectiveness of mHealth interventions in increasing HPV vaccine uptake among mothers of unvaccinated girls aged 9-14 years in Lagos, Nigeria.
View Article and Find Full Text PDFMenopause
September 2025
Department of Gynecologic Oncology, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY.
Objective: Endometrial cancer (EC) and epithelial ovarian cancer (EOC) affect women of all ages, and the incidence of endometrial cancer in premenopausal women is rising. Menopause can be detrimental to longevity and quality of life, but evidence suggests estrogen therapy (ET) is safe in these patients. The purpose of this study was to evaluate the practice patterns of gynecologists and gynecologic oncologists (GYO) in the United States in regards to prescription of ET to gynecologic cancer patients.
View Article and Find Full Text PDFPLOS Glob Public Health
September 2025
Department of Child, Family, and Population Health Nursing, School of Nursing, University of Washington, Seattle, Washington, United States of America.
Cervical cancer continues to be a major global threat to women's health, with approximately 660,000 women diagnosed annually, 94% of whom are in low- and middle-income countries (LMICs). The high disease burden in LMICs is partly due to suboptimal adoption and widespread implementation of effective preventive interventions. This study explored drivers of implementation success and failure for a future single-visit, screen, and treat approach with thermal ablation (SV-SAT + TA), referred to as TIBA in Kenya.
View Article and Find Full Text PDFAm J Case Rep
September 2025
Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan.
BACKGROUND This study reports on 2 cases of cervical melanoma with similar presentations but at different stages, and the treatment strategy varied accordingly, and we review the literature on the characteristics, diagnosis, and management of cervical melanoma. CASE REPORT Case 1: A 69-year-old woman with abnormal vaginal bleeding was diagnosed with advanced cervical melanoma, staged as International Federation of Gynecology and Obstetrics (FIGO) Stage IVB, involving multiple metastases. Despite chemoradiotherapy and immunotherapy (nivolumab), the disease progressed rapidly, and the patient died 4 months after diagnosis.
View Article and Find Full Text PDFObstet Gynecol
July 2025
Ana I. Tergas is from the Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Health, Rutgers New Jersey Medical School, Newark, New Jersey. Mark H. Einstein is from the Department of Obstetrics, Gynecology, and Women's Health, Albert Einstein College of Medicine